List of Excipients in Branded Drug CAMBIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Assertio Therapeutics Inc	CAMBIA	diclofenac potassium	13913-011	ASPARTAME
Assertio Therapeutics Inc	CAMBIA	diclofenac potassium	13913-011	GLYCERYL DIBEHENATE
Assertio Therapeutics Inc	CAMBIA	diclofenac potassium	13913-011	MANNITOL

CAMBIA Excipient Strategy and Commercial Opportunities for Diclofenac Potassium Oral Solution

Last updated: August 1, 2026

Cambia is a differentiated diclofenac potassium product that uses a rapidly dissolving, buffered powder for oral solution rather than a conventional tablet or capsule. Its commercial value depends on the combination of diclofenac potassium, potassium bicarbonate, mannitol, sweeteners, flavoring, and a low-moisture single-dose sachet. The main opportunities are generic substitution, reformulation without aspartame, improved taste, pediatric or dysphagia-friendly delivery, and geographic expansion of buffered diclofenac powder products.

Cambia’s excipient system is commercially relevant because it supports rapid dispersion, palatability, moisture protection, and use without swallowing a solid dosage form. The principal development constraint is that any generic or follow-on product must preserve key performance characteristics, including dissolution, dispersion, dose uniformity, stability, and clinical pharmacokinetics.

What is Cambia and how does its formulation work?

Cambia contains 50 mg of diclofenac potassium in a powder that is dissolved in water before oral administration. The FDA-approved indication is the acute treatment of migraine attacks with or without aura in adults. It is not indicated for prophylactic migraine treatment. The product is supplied in single-dose packets and is administered by dissolving the contents in approximately 1 to 2 ounces of water and consuming the solution immediately.[1]

The formulation uses a buffered, sweetened powder system:

Formulation component	Publicly identified role
Diclofenac potassium	Active pharmaceutical ingredient
Potassium bicarbonate	Buffering and effervescence-supporting excipient; promotes dispersion in water
Mannitol	Bulking agent, diluent, mouthfeel modifier and taste-masking aid
Aspartame	High-intensity sweetener
Acesulfame potassium	High-intensity sweetener
Saccharin sodium	Sweetness and taste masking
Colloidal silicon dioxide	Flow aid and anti-caking agent
Flavoring	Palatability and product acceptability

The product is designed for oral solution immediately before dosing, rather than as a premanufactured liquid. That approach avoids the long-term chemical and microbial stability problems associated with an aqueous diclofenac product while preserving a non-tablet route of administration.

What excipients protect the commercial performance of Cambia?

The most important excipient functions are rapid wetting, dispersion, taste masking, flowability and moisture control.

Potassium bicarbonate and buffered dispersion

Potassium bicarbonate likely contributes to the product’s rapid dispersibility when added to water. In an oral powder, the excipient can support a buffered environment and help the formulation break apart quickly. The buffering system also can affect diclofenac solubility, taste and gastrointestinal tolerability.

The excipient is strategically important because a substitute buffer may change:

• solution pH;
• diclofenac dissolution;
• precipitation after reconstitution;
• taste;
• packet stability;
• potassium load;
• bioequivalence risk.

A generic developer should treat the buffer system as a performance-critical component rather than as a routine inactive ingredient.

Mannitol and powder architecture

Mannitol provides bulk for a low-dose powder containing 50 mg of diclofenac potassium. It can improve mouthfeel and reduce the harsh taste associated with diclofenac salts and alkaline buffering agents. Mannitol also has a relatively established use profile in oral powders and can support a free-flowing blend.

The principal development risks are particle-size distribution, segregation, electrostatic behavior and moisture uptake. These variables affect dose uniformity and packet filling, especially when the active ingredient and excipients have materially different particle sizes or densities.

Sweetener system

Cambia uses multiple sweeteners rather than relying on a single taste-masking agent. Aspartame, acesulfame potassium and saccharin sodium provide complementary sweetness profiles and can reduce the bitterness and metallic or alkaline notes associated with diclofenac potassium and potassium bicarbonate.

The sweetener system creates a specific regulatory and commercial issue. Aspartame contains phenylalanine, requiring a warning for patients with phenylketonuria. An aspartame-free version could expand use among patients who avoid phenylalanine-containing products and could simplify product positioning.

Replacing aspartame is not a simple one-for-one substitution. Developers must reassess:

• sweetness intensity;
• aftertaste;
• solution pH;
• chemical compatibility;
• hygroscopicity;
• packet stability;
• comparative dissolution and reconstitution;
• labeling requirements.

Colloidal silicon dioxide

Colloidal silicon dioxide supports powder flow and reduces caking. Its value increases in a sachet product because poor flow can produce packet-to-packet variability and manufacturing stoppages.

Its use level and grade can affect blend uniformity. A change in particle size or surface area may alter flow without materially changing the nominal formulation, creating a process-validation and comparability issue.

Flavoring

Flavor is a commercial differentiator in an acute migraine product. Patients may experience nausea, vomiting or sensory sensitivity during a migraine attack. A flavor that is acceptable under ordinary conditions may perform poorly during an attack.

Commercial development should evaluate:

• low-intensity flavor systems;
• neutral or lightly flavored products;
• citrus, berry or mint profiles;
• reduced sweetness;
• sensory performance after immediate reconstitution;
• taste after partial dissolution;
• compatibility with common migraine-related nausea.

The label instructs patients to dissolve the powder in water and consume it immediately. Flavor and mouthfeel therefore have direct effects on adherence.

What formulation patents protect Cambia?

Cambia’s protection is likely divided among product patents, formulation claims, use claims and regulatory exclusivity. The public FDA labeling establishes the approved dosage form and excipient system, but it does not by itself establish the full scope of the patent estate.

The relevant patent categories are:

Patent category	Commercial relevance
Diclofenac potassium composition claims	Protect the active pharmaceutical ingredient or specific salt form
Buffered powder claims	Protect the combination of diclofenac potassium with buffering agents
Oral solution or rapid-dispersion claims	Protect reconstitution and dissolution performance
Sachet or moisture-barrier packaging claims	Protect stability and dose presentation
Migraine method-of-use claims	May constrain labeling for acute migraine treatment
Manufacturing-process claims	May create production barriers even where composition claims are weak
Pediatric or administration claims	Could protect specific populations or dosing approaches

The original diclofenac molecule and conventional diclofenac potassium products are long off patent. Any meaningful exclusivity for Cambia therefore depends on formulation, delivery, manufacturing or use claims rather than basic API ownership.

An Orange Book analysis should distinguish between:

1. patents listed for the approved NDA;
2. patents that have expired;
3. patents still listed but no longer capable of blocking all generic entry;
4. patents that may support a Paragraph IV certification;
5. patents that protect only a narrow formulation or use.

A developer should not infer that a listed patent prevents a competing product. Patent scope, expiration, claim construction, infringement exposure and the proposed generic label determine the actual risk.

When does Cambia lose exclusivity?

Cambia received FDA approval in 2010 under NDA 022202.[1] The product’s regulatory exclusivity period has expired. Conventional five-year new chemical entity exclusivity does not apply in the same way because diclofenac was previously approved and Cambia is a reformulated product.

The commercial entry question is therefore controlled primarily by patents and FDA approval of competing ANDAs, not by remaining new-drug exclusivity.

Exclusivity timeline

Event	Date or status
FDA approval of Cambia	2010
Approved indication	Acute treatment of migraine in adults
NCE exclusivity	Not the principal protection for Cambia
Regulatory exclusivity today	Expired
Current entry barrier	Listed patents, formulation differentiation, manufacturing capability and commercial execution
Biosimilar pathway	Not applicable; diclofenac is a small molecule
Generic pathway	ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act

The relevant generic pathway is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. A proposed generic powder for oral solution would need to match the reference product’s dosage form, route, strength and relevant quality attributes.

Which companies are challenging Cambia?

Cambia is a small-molecule product, so the competitive field consists of generic-drug manufacturers, branded acute-migraine companies and alternative diclofenac products. Biosimilar manufacturers are not relevant.

Publicly available information should be checked against the current FDA Orange Book and Abbreviated New Drug Application records before relying on any specific company, Paragraph IV certification or litigation position. A generic manufacturer can challenge a listed patent through:

• Paragraph IV certification;
• a section viii statement for a method-of-use patent;
• a patent expiration certification;
• an ANDA that omits a protected indication where permitted.

A section viii strategy may be commercially attractive if the relevant patent claims only acute migraine treatment and the generic can lawfully market a label that omits the patented use. That strategy depends on the exact claim language, FDA labeling requirements and whether the proposed product can be marketed without inducing infringement.

What Paragraph IV risks exist for Cambia?

The highest-risk Paragraph IV targets would be narrow claims covering the powder formulation, buffer combination, rapid reconstitution or packet presentation.

A challenger would likely focus on prior art involving:

• oral diclofenac salts;
• effervescent or buffered powders;
• mannitol-containing oral sachets;
• sweetened pharmaceutical powders;
• rapid-release diclofenac products;
• migraine treatment with oral diclofenac.

The patent-strength analysis should examine four factors:

Factor	Key question
Novelty	Does the claimed excipient combination differ from earlier diclofenac powders?
Obviousness	Would a formulator reasonably combine the claimed buffer, bulking agent and sweeteners?
Written description	Does the patent disclose the full scope of the claimed composition?
Infringement	Does the generic product practice every required claim element?

A formulation patent can have meaningful commercial value even if it has a narrow claim set. The value depends on whether the claim covers the minimum formulation needed to reproduce Cambia’s dissolution, taste and stability profile.

How strong is the Cambia patent estate?

Cambia’s likely patent strength is mixed.

The basic active ingredient position is weak because diclofenac and diclofenac potassium are longstanding products. A later formulation estate can be stronger if it claims a specific and non-obvious combination that produces rapid dissolution, acceptable taste or improved migraine pharmacokinetics.

Stronger potential claim areas

• tightly defined diclofenac potassium and buffer ratios;
• reconstitution performance;
• specific pH or dissolution limits;
• moisture-stable powder compositions;
• manufacturing controls that produce a reproducible powder;
• packaging systems necessary to maintain stability.

Weaker potential claim areas

• broad claims to diclofenac potassium in a powder;
• generic use of mannitol as a diluent;
• broad claims to sweetened oral diclofenac;
• conventional single-dose packaging;
• broad migraine treatment claims without a distinctive delivery feature.

The practical barrier may be manufacturing know-how rather than patent scope. Producing a stable, free-flowing and taste-acceptable powder can require process controls that are difficult to reproduce from the public label alone.

What generic launch scenarios exist for Cambia?

Scenario 1: Full-label generic launch

A generic manufacturer markets diclofenac potassium powder for oral solution with the same acute migraine indication. This is the most direct substitution strategy and creates the highest exposure to formulation and method-of-use patents.

Scenario 2: Section viii carve-out

The applicant omits a patented indication while retaining other approved uses, if the FDA and patent claims permit that approach. Cambia’s migraine-specific positioning could make a carve-out difficult if acute migraine treatment is the only commercially meaningful indication.

Scenario 3: Formulation redesign

The challenger changes the sweetener, flavor, buffer or packaging system. This may reduce literal infringement risk but increases bioequivalence, stability and sensory-development risk.

Scenario 4: Authorized or licensed generic

The brand owner or commercial partner supplies an authorized generic. This can preserve channel access while reducing the price gap created by independent ANDA competition.

Scenario 5: Delayed commercial launch

An ANDA is approved but launch is delayed because the product has weak economics, manufacturing constraints or limited pharmacy demand. Cambia’s specialized dosage form may require more education and distribution support than a conventional diclofenac tablet.

What excipient reformulations create the best commercial opportunities?

Aspartame-free Cambia-style product

An aspartame-free formulation is the clearest line-extension opportunity. It removes the phenylketonuria warning and may appeal to patients seeking products without aspartame.

Potential replacements include sucralose, steviol glycosides, acesulfame potassium, saccharin or sugar alcohol systems. Each option creates different taste, stability and regulatory considerations. A high-intensity sweetener blend would likely be preferable to a single replacement because diclofenac and bicarbonate have multiple taste defects.

Low-sodium or potassium-conscious formulation

Cambia uses potassium bicarbonate. A reformulated product could investigate alternative buffering systems, subject to maintaining solubility, stability and acceptable electrolyte exposure.

This opportunity is technically more complex because changing the counterion or buffer can alter the active ingredient’s dissolution and pharmacokinetic behavior. It may also create a new formulation patent position if the resulting performance is unexpected.

Neutral-flavor formulation

A neutral or minimally flavored sachet could be useful for patients with migraine-related sensory sensitivity. This could reduce the risk that flavor becomes unacceptable during an attack.

Dysphagia and nausea-oriented delivery

The powder-for-solution format already avoids swallowing a tablet. Improvements could include:

• faster reconstitution;
• smaller water volume;
• stick packs;
• tear-open packaging;
• clearer mixing instructions;
• dose preparation that remains practical during nausea;
• compatibility with orally disintegrating or buccal delivery systems.

These changes may support new product claims, but they must preserve the reference product’s dosage form and performance if marketed as a generic.

Pediatric formulation

Cambia is approved for adults. A pediatric product could target adolescent migraine, subject to clinical development, dosing work and FDA approval. The excipient strategy would need tighter control of sweetener exposure, flavor intensity, packet size and dose flexibility.

How does Cambia compare with other acute migraine products?

Product category	Dosage form	Excipient opportunity	Main commercial advantage
Cambia	Diclofenac potassium powder for oral solution	Buffer, sweetener, flavor and packet optimization	Non-tablet acute NSAID delivery
Diclofenac tablets	Solid oral dosage form	Conventional coating and disintegration systems	Low cost and broad generic availability
Triptans	Tablets, nasal sprays, injections	Taste masking and rapid delivery	Migraine-specific pharmacology
CGRP antagonists	Tablets or orally disintegrating products	Solubilizers, disintegrants and taste masking	Newer mechanism and non-NSAID positioning
NSAID combinations	Tablets or capsules	Combination stability and release control	Multi-mechanism symptom relief
Nasal migraine products	Nasal spray or powder	Mucoadhesive and permeation systems	Avoids gastrointestinal administration

Cambia’s differentiation is primarily delivery-based. Its active ingredient is familiar, but the powder-for-solution presentation may provide a patient-experience advantage over tablets for patients who have difficulty swallowing during migraine attacks.

What FDA regulatory issues apply to Cambia excipients?

The FDA regulates excipients through the finished-product review. An excipient does not need to be independently approved as a drug, but the proposed amount, route, population and formulation context must be acceptable.

Key regulatory areas include:

• inactive-ingredient safety;
• maximum daily exposure;
• phenylalanine labeling for aspartame;
• elemental potassium exposure;
• microbial and chemical stability;
• residual moisture;
• dissolution and reconstitution;
• powder flow and content uniformity;
• packaging integrity;
• flavoring documentation;
• comparative bioavailability.

For an ANDA, a formulation that differs materially from the reference product may trigger additional questions even if the dosage form remains a powder for oral solution. A reformulator should generate comparative data on solution pH, appearance, reconstitution time, assay, impurities, dissolution and stability.

The FDA’s Inactive Ingredient Database can support early excipient selection, but prior use in another product does not eliminate the need to justify the proposed formulation and exposure.[2]

What manufacturing and intellectual-property barriers affect Cambia?

The principal manufacturing barrier is control of a low-dose, multicomponent powder blend. Relevant process variables include:

• active and excipient particle-size distribution;
• blending order;
• segregation during transfer;
• electrostatic charging;
• moisture exposure;
• filling accuracy;
• seal integrity;
• sachet permeability;
• reconstitution time;
• batch-to-batch flavor consistency.

A robust process may require granulation, controlled blending or engineered particle-size matching. Those process choices can create protectable manufacturing know-how even if the final excipient list is public.

Packaging is also important. A moisture-sensitive powder may require high-barrier foil laminate or equivalent protection. A lower-cost package can increase caking, reduce flow and change dissolution during shelf life.

What licensing deals and commercial partnerships matter?

Cambia’s commercial opportunity is suitable for several licensing models:

Model	Strategic use
Regional license	Expands access in markets where oral diclofenac powders are underdeveloped
Generic supply agreement	Uses an established manufacturer while preserving brand control
Authorized generic	Captures lower-price demand before or after independent generic entry
Formulation license	Licenses an aspartame-free, improved-taste or low-volume reconstitution product
Co-development agreement	Funds pediatric, geographic or alternative-delivery development
API and finished-dose supply	Reduces manufacturing investment for smaller markets

The strongest licensing asset would be a formulation with measurable advantages, such as faster reconstitution, improved sensory acceptance, lower moisture sensitivity or a clinically supported adherence benefit. An excipient substitution alone is unlikely to command significant licensing value unless it creates a defensible patent position or solves a regulatory and commercial problem.

What is the revenue exposure to generic entry?

Cambia’s revenue exposure depends on the proportion of sales generated by the branded powder presentation rather than by the broader diclofenac market. Generic entry would likely produce rapid price erosion if multiple ANDA sponsors launch interchangeable products.

The likely sequence is:

1. first generic approval or launch;
2. payer substitution and formulary pressure;
3. pharmacy-level substitution;
4. loss of premium pricing;
5. stabilization around manufacturing cost and distribution economics.

The product may retain a niche if patients value its powder format, flavor, rapid preparation or brand familiarity. A differentiated brand strategy should therefore focus on patient experience rather than on diclofenac as an ingredient.

Key Takeaways

• Cambia is a 50 mg diclofenac potassium powder for oral solution approved for acute migraine treatment in adults.
• Its commercial differentiation comes from the excipient and delivery system, not from the underlying diclofenac molecule.
• Potassium bicarbonate, mannitol, sweeteners, colloidal silicon dioxide and flavoring collectively support dispersion, taste, flow and stability.
• Regulatory exclusivity has expired; future entry risk depends on listed patents, ANDA strategy and manufacturing execution.
• The product is subject to generic risk, not biosimilar risk.
• An aspartame-free reformulation is the clearest excipient-led commercial opportunity.
• Other opportunities include neutral flavor, lower-volume reconstitution, pediatric dosing and improved moisture-stable packaging.
• The strongest remaining intellectual-property positions are likely to involve specific composition ratios, dissolution performance, manufacturing processes or packaging systems.
• Commercial protection will weaken materially if a generic reproduces the patient experience at substantially lower cost.

FAQs About Cambia Excipient Strategy and Market Opportunities

Can Cambia be reformulated without aspartame?

Yes. An aspartame-free version could use other high-intensity sweeteners or a blended sweetener system. The reformulation would require comparative testing for taste, stability, pH, dissolution, reconstitution and labeling.

Is Cambia a biologic eligible for biosimilar competition?

No. Cambia contains diclofenac potassium, a small-molecule active ingredient. Competing products would generally use the ANDA generic-drug pathway rather than the biosimilar pathway.

Does potassium bicarbonate make Cambia clinically different from diclofenac tablets?

The buffer contributes to the powder’s reconstitution and formulation performance. It does not, by itself, establish a separate therapeutic mechanism from diclofenac. Clinical differences depend on the complete formulation and resulting pharmacokinetics.

Could a generic use different excipients from Cambia?

Yes, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, quality and labeling. A materially different excipient system may reduce patent risk but can increase development and regulatory risk.

What is the most defensible new product based on Cambia’s excipient platform?

An aspartame-free, rapidly reconstituting, neutral-flavor or low-volume powder for oral solution is the most direct opportunity. A pediatric version could offer greater market differentiation but would require additional clinical and regulatory development.

References

1. U.S. Food and Drug Administration. (2010). Cambia (diclofenac potassium) for oral solution prescribing information. NDA 022202.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Food and Drug Administration. (2013). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.
5. U.S. Food and Drug Administration. (2023). Cambia: Diclofenac potassium for oral solution, Drug Trials Snapshots and labeling materials.